GoodRx launches a $39 weight-loss telehealth subscription and lists the $199 GLP-1 cash price

GoodRx said on Nov. 17, 2025 that it has launched a direct-to-consumer telemedicine subscription for weight management priced at $39 per month, and — through a collaboration with Novo Nordisk — is listing an introductory self-pay price of $199 per month for Ozempic (semaglutide) and Wegovy (semaglutide) injection pens ^[1].

Both prices come with time limits and conditions. The $39 subscription is an introductory rate available through January 2026; the standard price becomes $119 per month starting Feb. 1, 2026 ^[1]. Medications are billed separately from the subscription, which GoodRx says lets customers "only pay for what they need" ^[1].

What the $199 price actually covers

The $199 monthly price applies to first-time GoodRx users for the first two fills, and only at the two lowest doses — 0.25 mg and 0.5 mg ^[1]. After those two months, the price moves to $349 per month for later fills ^[1]. GoodRx says the self-pay cost for Ozempic 2.0 mg remains $499 ^[1]. The offer is valid through March 31, 2026 ^[1].

That structure matters because 0.25 mg and 0.5 mg are starting doses in semaglutide's stepped titration. The company's own footnote makes clear the $199 figure is a two-month entry price, not an ongoing monthly cost ^[1].

On fulfillment, GoodRx says the subscription offers in-store pickup at "nearly all retail pharmacy locations nationwide" for Wegovy or Zepbound (tirzepatide) pens, plus home delivery for the Zepbound vial formulation through LillyDirect ^[1]. The service also includes virtual consultations with licensed providers who determine eligibility and, if appropriate, write a prescription, along with ongoing clinical support to track progress, manage side effects and adjust treatment ^[1].

GoodRx framed the launch partly as a contrast with compounded products. "We're committed to connecting consumers with FDA-approved GLP-1 medications backed by science and safety, not compounded alternatives that fall short of those standards," said Wendy Barnes, GoodRx president and CEO ^[1]. The company describes itself as used by nearly 30 million consumers and more than one million healthcare professionals annually, and says it has helped Americans save over $85 billion on medication costs since 2011 ^[1].

Why it matters for patients

For people paying cash, the headline numbers are easy to misread. Adding the pieces together as GoodRx describes them: in the first two months a new user at a starting dose would face $199 for the drug plus the subscription fee if they need a prescription through GoodRx; by month three the listed drug price is $349, and after Feb. 1, 2026 the subscription's standard price is $119 ^[1]. The press release does not state a combined total, and it does not say whether the $199 or $349 prices require an active subscription or are available to anyone who already has a prescription — it says people who already have a prescription can search for Ozempic or Wegovy on GoodRx to get prices "as low as $199 per month for the first two fills" ^[1].

Several practical details are not in the announcement. It does not say what happens to the cash price at doses between 0.5 mg and 2.0 mg other than the $349 standard price, nor whether the $349 price has an end date beyond the March 31, 2026 offer window ^[1]. It does not describe eligibility rules for the telehealth service, refund or cancellation terms, what happens if a prescriber decides a GLP-1 is not appropriate, or whether insurance can be combined with these cash prices ^[1]. Those gaps are worth noting because GLP-1 treatment for weight management is typically long-term, and dose escalation is standard.

The announcement also underscores how cash-pay channels are multiplying. GoodRx is listing Novo Nordisk's self-pay semaglutide pens alongside Eli Lilly's Zepbound pens in retail pharmacies and Zepbound vials shipped through LillyDirect, all inside one subscription ^[1].

What happens next

• Through January 2026: GoodRx for Weight Loss subscription available at the $39 introductory rate ^[1].
• Feb. 1, 2026: Subscription standard price rises to $119 per month ^[1].
• March 31, 2026: The $199 introductory drug offer expires ^[1].

GoodRx cautions in its forward-looking statements that its plans involve risks including "changes in medication pricing and pricing structures" and reliance on a limited number of industry participants ^[1]. In other words, the prices announced this week are not guaranteed to hold beyond the stated dates.